ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "3069177f-d7a2-4b0e-a54d-3838076a6ca0"}, "_deposit": {"id": "2015563", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2015563"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02015563", "sets": ["1642838224252", "1642838412624"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "\uff3b\u7dcf\u8aac\uff3d\u672b\u68a2\u52d5\u8108\u75be\u60a3\u306b\u5bfe\u3059\u308b\u85ac\u7269\uff0b\u904b\u52d5\u7642\u6cd5", "subitem_1551255648112": "ja"}, {"subitem_1551255647225": "Exercise and Pharmacological Intervention for Patient  with Peripheral Arterial Disease", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u5b89, \u9686\u5247", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "Yasu, Takanori", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "ja", "subitem_1522651041219": "\u7409\u7403\u533b\u5b66\u4f1a"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "exercise"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "intermittent"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "claudication"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "heparin"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "peripheral"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "arterial"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "disease"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Trans Atlanticinter-Society Consensus (TASC)) II strongly recommends walking exercise and anti-platelet agents for patients with peripheral arterial disease(PAD).We have reported that a program combining heparin administration with exerciseis a useful therapeutic strategy for stimulation of collateral development in ischemic legs in patients with non-Option PAD via transient increase in hepatocyte growth factor. To examine a hypothesis that additional combination of lipo-Prestaglandin(PG\uff09E1,a Potent vasodilator and inhibitor of platelet aggregation, accelerates the effectiveness of heparin + exercise program in patients with non-option PAD, 20 symptomatic no option PAD (Fontaine II or III\uff09patients were randomly assigned in adouble blind fashion to two groups; a group of lipo-PGEl(+) (supervised walking for 60min/day after intravenous administration of 3,000 units heparin and 10 $ \\mu $g lipo-PGE1 for 14days, n=10) and a group of lipo-PGEl(-) (same supervised walking program after administration of heparin and saline,n=10). After 14-day-initial treatment,the patients of both groups did ambulatory exercise under supervision for 60 min once a day, 3 days/week during a period of following 22 weeks. Additional administration of lipo-PGE1 on heparin + exercise program brings the therapeutic gain appearance forward\uff0eThis beneficial short-term effect may encourage patients with non-Option PAD to maintain exercise trainlng.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "ja", "subitem_1522300316516": "\u7409\u7403\u533b\u5b66\u4f1a"}, {"subitem_1522300295150": "en", "subitem_1522300316516": "Ryukyu Medical Association"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "jpn"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1346-888X"}, {"subitem_1522646500366": "ISSN", "subitem_1522646572813": "0289-1530"}, {"subitem_1522646500366": "NCID", "subitem_1522646572813": "AN10369445"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "ja", "subitem_1522650091861": "\u7409\u7403\u533b\u5b66\u4f1a\u8a8c = Ryukyu Medical Journal"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueNumber": "3\u30fb4", "bibliographicPageEnd": "98", "bibliographicPageStart": "95", "bibliographicVolumeNumber": "26"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "v26p95.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2015563/files/v26p95.pdf"}, "version_id": "17009a5d-9602-49b8-a1e6-4f374897e44c"}]}, "item_title": "\uff3b\u7dcf\u8aac\uff3d\u672b\u68a2\u52d5\u8108\u75be\u60a3\u306b\u5bfe\u3059\u308b\u85ac\u7269\uff0b\u904b\u52d5\u7642\u6cd5", "item_type_id": "15", "owner": "1", "path": ["1642838224252", "1642838412624"], "permalink_uri": "http://hdl.handle.net/20.500.12000/0002015563", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2010-02-23"}, "publish_date": "2010-02-23", "publish_status": "0", "recid": "2015563", "relation": {}, "relation_version_is_last": true, "title": ["\uff3b\u7dcf\u8aac\uff3d\u672b\u68a2\u52d5\u8108\u75be\u60a3\u306b\u5bfe\u3059\u308b\u85ac\u7269\uff0b\u904b\u52d5\u7642\u6cd5"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. 琉球医学会
  3. 琉球医学会誌
  4. 26巻3・4号
  1. 部局別インデックス
  2. その他

[総説]末梢動脈疾患に対する薬物+運動療法

http://hdl.handle.net/20.500.12000/0002015563
http://hdl.handle.net/20.500.12000/0002015563
4526d455-d399-47bb-af8f-c7802f706a79
名前 / ファイル ライセンス アクション
v26p95.pdf v26p95.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2010-02-23
タイトル
タイトル [総説]末梢動脈疾患に対する薬物+運動療法
言語 ja
作成者 安, 隆則

× 安, 隆則

ja 安, 隆則

Yasu, Takanori

× Yasu, Takanori

en Yasu, Takanori

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 ja
権利情報 琉球医学会
主題
言語 en
主題Scheme Other
主題 exercise
言語 en
主題Scheme Other
主題 intermittent
言語 en
主題Scheme Other
主題 claudication
言語 en
主題Scheme Other
主題 heparin
言語 en
主題Scheme Other
主題 peripheral
言語 en
主題Scheme Other
主題 arterial
言語 en
主題Scheme Other
主題 disease
内容記述
内容記述タイプ Other
内容記述 Trans Atlanticinter-Society Consensus (TASC)) II strongly recommends walking exercise and anti-platelet agents for patients with peripheral arterial disease(PAD).We have reported that a program combining heparin administration with exerciseis a useful therapeutic strategy for stimulation of collateral development in ischemic legs in patients with non-Option PAD via transient increase in hepatocyte growth factor. To examine a hypothesis that additional combination of lipo-Prestaglandin(PG)E1,a Potent vasodilator and inhibitor of platelet aggregation, accelerates the effectiveness of heparin + exercise program in patients with non-option PAD, 20 symptomatic no option PAD (Fontaine II or III)patients were randomly assigned in adouble blind fashion to two groups; a group of lipo-PGEl(+) (supervised walking for 60min/day after intravenous administration of 3,000 units heparin and 10 $ \mu $g lipo-PGE1 for 14days, n=10) and a group of lipo-PGEl(-) (same supervised walking program after administration of heparin and saline,n=10). After 14-day-initial treatment,the patients of both groups did ambulatory exercise under supervision for 60 min once a day, 3 days/week during a period of following 22 weeks. Additional administration of lipo-PGE1 on heparin + exercise program brings the therapeutic gain appearance forward.This beneficial short-term effect may encourage patients with non-Option PAD to maintain exercise trainlng.
内容記述タイプ Other
内容記述 論文
出版者
言語 ja
出版者 琉球医学会
言語
言語 jpn
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1346-888X
収録物識別子タイプ ISSN
収録物識別子 0289-1530
収録物識別子タイプ NCID
収録物識別子 AN10369445
収録物名
言語 ja
収録物名 琉球医学会誌 = Ryukyu Medical Journal
書誌情報
巻 26, 号 3・4, p. 95-98
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-22 03:00:38.913196
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3